Page 2118 - Williams Hematology ( PDFDrive )

2092 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2093

393. Stuijver DJ, Piantanida E, van Zaane B, et al: Acquired von Willebrand syndrome 426. Valeri CR, Cassidy G, Pivacek LE, et al: Anemia-induced increase in the bleeding time:
in patients with overt hypothyroidism: A prospective cohort study. Haemophilia Implications for treatment of nonsurgical blood loss. Transfusion 41(8):977–983, 2001.
20(3):326–332, 2014. 427. Castillo R, Lozano T, Escolar G, et al: Defective platelet adhesion on vessel subendothe-
394. Wiegand G, Hofbeck M, Zenker M, et al: Bleeding diathesis in Noonan syndrome: Is lium in uremic patients. Blood 68(2):337–342, 1986.
acquired von Willebrand syndrome the clue? Thromb Res 130(5):e251–e254, 2012. 428. Livio M, Gotti E, Marchesi D, et al: Uraemic bleeding: Role of anaemia and beneficial
395. Mazurier C, Parquet-Gernez A, Descamps J, et al: Acquired von Willebrand’s syndrome effect of red cell transfusions. Lancet 2(8306):1013–1015, 1982.
in the course of Waldenström’s disease. Thromb Haemost 44(3):115–118, 1980. 429. Fernandez F, Goudable C, Sie P, et al: Low haematocrit and prolonged bleeding time in
396. Handin RI, Martin V, Moloney WC: Antibody-induced von Willebrand’s disease: uraemic patients: Effect of red cell transfusions. Br J Haematol 59:139–148, 1985.
A newly defined inhibitor syndrome. Blood 48(3):393–405, 1976. 430. Moia M, Mannucci PM, Vizzotto L, et al: Improvement in the haemostatic defect of
397. Van Genderen PJ, Papatsonis DN, Michiels JJ, et al: High-dose intravenous gamma- uraemia after treatment with recombinant human erythropoietin. Lancet 2:1227–1229,
globulin therapy for acquired von Willebrand disease. Postgrad Med J 70(830):916–920, 1987.
1994. 431. Tang WW, Stead RA, Goodkin DA: Effects of epoetin alfa on hemostasis in chronic
398. Goudemand J, Samor B, Caron C, et al: Acquired type II von Willebrand’s disease: renal failure. Am J Nephrol 18:263–273, 1998.
Demonstration of a complexed inhibitor of the von Willebrand factor-platelet interac- 432. Turrito VT, Weiss HJ: Red blood cells: Their dual role in thrombus formation. Science
tion and response to treatment. Br J Haematol 68(2):227–233, 1988. 207:541, 1980.
399. Mohri H, Hisanaga S, Mishima A, et al: Autoantibody inhibits binding of von Wille- 433. Casonato A, Pontara E, Vertolli UP, Steffan A, Durante C, De Marco L, Sartorello F,
brand factor to glycoprotein Ib and collagen in multiple myeloma: Recognition sites Girolami A: Plasma and platelet von Willebrand factor abnormalities in patients with
present on the A1 loop and A3 domains of von Willebrand factor. Blood Coagul uremia: Lack of correlation with uremic bleeding. Clin Appl Thromb Hemost 7(2):81–
Fibrinolysis 9(1):91–97, 1998. 86, 2001.
400. Igarashi N, Miura M, Kato E, et al: Acquired von Willebrand’s syndrome with lupus-like 434. Zwaginga JJ, Ijsseldijk MJ, Beeser-Visser N, et al: High von Willebrand factor concentra-
serology. Am J Pediatr Hematol Oncol 11(1):32–35, 1989. tion compensates a relative adhesion defect in uremic blood. Blood 75:1498–1508, 1990.
401. Agrawal AK, Golden C, Matsunaga A: Acquired von Willebrand disease in an osteosa- 435. Sloand EM, Sloand JA, Prodouz K, et al: Reduction of platelet glycoprotein Ib in ure-
rcoma patient. J Pediatr Hematol Oncol 33(8):622–623, 2011. mia. Br J Haematol 77:375–381, 1991.
402. Scott JP, Montgomery RR, Tubergen DG, Hays T: Acquired von Willebrand’s disease 436. Gralnick HR, McKeown LP, Williams SB, et al: Plasma and platelet von Willebrand
in association with Wilms’ [sic] tumor: Regression following treatment. Blood 58(4): factor defects in uremia. Am J Med 85:806–810, 1988.
665–669, 1981. 437. Escolar G, Cases A, Bastida E, et al: Uremic platelets have a functional defect affecting
403. Rao KP, Kizer J, Jones TJ, et al: Acquired von Willebrand’s syndrome associated with an the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76:1336–
extranodal pulmonary lymphoma. Arch Pathol Lab Med 112(1):47–50, 1988. 1340, 1990.
404. Baxter PA, Nuchtern JG, Guillerman RP, et al: Acquired von Willebrand syndrome and 438. Di Minno G, Cerbone A, Usberti M, et al: Platelet dysfunction in uremia. II. Correc-
Wilms tumor: Not always benign. Pediatr Blood Cancer 52(3):392–394, 2009. tion by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine
405. Levesque H, Borg JY, Cailleux N, et al: Acquired von Willebrand’s syndrome associated diphosphate or collagen. J Lab Clin Med 108:246–252, 1986.
with decrease of plasminogen activator and its inhibitor during hypothyroidism. Eur J 439. Rabiner SF, Hrodek O: Platelet factor 3 in normal subjects and patients with renal fail-
Med 2(5):287–288, 1993. ure. J Clin Invest 47(4):901–912, 1968.
406. Aylesworth CA, Smallridge RC, Rick ME, Alving BM: Acquired von Willebrand’s dis- 440. Ware JA, Clark BA, Smith M, Salzman EW: Abnormalities of cytoplasmic Ca in plate-
2+
ease: A rare manifestation of postpartum thyroiditis. Am J Hematol 50(3):217–219, lets from patients with uremia. Blood 73:172–176, 1989.
1995. 441. Mannucci PM, Remuzzi G, Pusineri F, et al: Deamino-8-arginine vasopressin shortens
407. Tiede A, Priesack J, Werwitzke S, et al: Diagnostic workup of patients with acquired von the bleeding time in uremia. N Engl J Med 308(1):8–12, 1983.
Willebrand syndrome: A retrospective single-centre cohort study. J Thromb Haemost 442. Winter M, Frampton G, Bennett A, et al: Synthesis of thromboxane B in uraemia and
2
6(4):569–576, 2008. the effects of dialysis. Thromb Res 30:265–272, 1983.
408. Joist JH, Cowan JF, Zimmerman TS: Acquired von Willebrand’s disease. Evidence for a 443. Neirynck N, Vanholder R, Schepers E, et al: An update on uremic toxins. Int Urol Neph-
quantitative and qualitative factor VIII disorder. N Engl J Med 298(18):988–991, 1978. rol 45(1):139–150, 2013.
409. Cushing M, Kawaguchi K, Friedman KD, Mark T: Factor VIII/von Willebrand factor 444. Bazilinski N, Shaykh M, Dunea G, et al: Inhibition of platelet function by uremic mid-
concentrate therapy for ventricular assist device-associated acquired von Willebrand dle molecules. Nephron 40:423–428, 1985.
disease. Transfusion 52(7):1535–1541, 2012. 445. Remuzzi G, Livio M, Marchiaro G, et al: Bleeding in renal failure: Altered platelet func-
410. Jimenez AR, Vallejo ES, Cruz MZ, et al: Rituximab effectiveness in a patient with juve- tion in chronic uraemia only partially corrected by haemodialysis. Nephron 22:347–
nile systemic lupus erythematosus complicated with acquired von Willebrand syn- 353, 1978.
drome. Lupus 22(14):1514–1517, 2013. 446. Livio M, Benigni A, Remuzzi G: Coagulation abnormalities in uremia. Semin Neprhol
411. Sucker C, Scharf RE, Zotz RB: Use of recombinant factor VIIa in inherited and acquired 5:82–90, 1985.
von Willebrand disease. Clin Appl Thromb Hemost 15(1):27–31, 2009. 447. Siqueira MA, Brunini TM, Pereira NR, et al: Increased nitric oxide production in plate-
412. Macik BG, Gabriel DA, White GC 2nd, et al: The use of high-dose intravenous gamma- lets from severe chronic renal failure patients. Can J Physiol Pharmacol 89(2):97–102,
globulin in acquired von Willebrand syndrome. Arch Pathol Lab Med 112(2):143–146, 2011.
1988. 448. Meenakshi SR, Agarwal R: Nitric oxide levels in patients with chronic renal disease.
413. Rinder MR, Richard RE, Rinder HM: Acquired von Willebrand’s disease: A concise Journal of clinical and diagnostic research: J Clin Diagn Res 7(7):1288–1290, 2013.
review. Am J Hematol 54(2):139–145, 1997. 449. Remuzzi G, Perico N, Zoja C, et al: Role of endothelium-derived nitric oxide in the
414. Franchini M, Lippi G: Recent acquisitions in acquired and congenital von Willebrand bleeding tendency of uremia. J Clin Invest 86(5):1768–1771, 1990.
disorders. Clin Chim Acta 377(1–2):62–69, 2007. 450. Aiello S, Noris M, Todeschini M, et al: Renal and systemic nitric oxide synthesis in rats
415. Biondo F, Matturro A, Santoro C, et al: Remission of acquired von Willebrand syn- with renal mass reduction. Kidney Int 52:171–181, 1997.
drome after successful treatment of gastric MALT lymphoma. Haemophilia 18(1):e34– 451. Noris M, Remuzzi G: Uremic bleeding: Closing the circle after 30 years of controver-
e35, 2012. sies? Blood 94(8):2569–2574, 1999.
416. Oliveira MC, Kramer CK, Marroni CP, et al: Acquired factor VIII and von Willebrand 452. Mendes Ribeiro AC, Brunini TM, Ellory JC, Mann GE: Abnormalities in L-arginine
factor (aFVIII-VWF) deficiency and hypothyroidism in a case with hypopituitarism. transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc
Clin Appl Thromb Hemost 16(1):107–109, 2010. Res 49(4):697–712, 2001.
417. Manfredi E, van Zaane B, Gerdes VE, et al: Hypothyroidism and acquired von Wille- 453. Brunini TM, Yaqoob MM, Novaes Malagris LE, et al: Increased nitric oxide synthesis in
brand’s syndrome: A systematic review. Haemophilia 14(3):423–433, 2008. uraemic platelets is dependent on L-arginine transport via system y(+)L. Pflugers Arch
418. Budde U, Scharf RE, Franke P, et al: Elevated platelet count as a cause of abnormal von 445(5):547–550, 2003.
Willebrand factor multimer distribution in plasma. Blood 82:1749–1757, 1993. 454. Linthorst GE, Avis HJ, Levi M: Uremic thrombocytopathy is not about urea. J Am Soc
419. Franchini M, Mannucci PM: Von Willebrand disease-associated angiodysplasia: A few Nephrol 21(5):753–755, 2010.
answers, still many questions. Br J Haematol 161(2):177–182, 2013. 455. Remuzzi G: Bleeding disorders in uremia: Pathophysiology and treatment. Adv Nephrol
420. Solomon C, Budde U, Schneppenheim S, et al: Acquired type 2A von Willebrand Necker Hosp 18:171–186, 1989.
syndrome caused by aortic valve disease corrects during valve surgery. Br J Anaesth 456. Andrassy K, Ritz E: Uremia as a cause of bleeding. Am J Nephrol 5:313, 1985.
106(4):494–500, 2011. 457. Ando M, Iwamoto Y, Suda A, et al: New insights into the thrombopoietic status of
421. Rao AK: Uraemic platelets. Lancet 1:913, 1986. patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow
422. Boccardo P, Remuzzi G, Galbusera M: Platelet dysfunction in renal failure. Semin and of endogenous thrombopoietin levels. Blood 2001;97(4):915–921, 1989.
Thromb Hemost 30(5):579–589, 2004. 458. George CRP, Slichter SJ, Quadracci LJ: A kinetic evaluation of hemostasis in renal
423. Rosenbaum R, Hoffstein PE, Stanley RJ, Klahr S: Use of computerized tomography to disease. N Engl J Med 291:1111, 1974.
diagnose complications of percutaneous renal biopsy. Kidney Int 14:87–92, 1978. 459. Linthorst GE, Folman CC, van Olden RW, von dem Borne AE. Plasma thrombopoietin
424. Diaz-Buxo JA, Donadio JVJ: Complications of percutaneous renal biopsy: An analysis levels in patients with chronic renal failure. Hematol J 3(1):38–42, 2002.
of 1000 consecutive biopsies. Clin Nephrol 4:223, 1975. 460. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a
425. Mannucci PM, Tripodi A: Hemostatic defects in liver and renal dysfunction. Hematol- transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group.
ogy Am Soc Hematol Educ Program 168–173, 2012. N Engl J Med 325(18):1261–1266, 1991.

Kaushansky_chapter 121_p2073-2096.indd 2093 9/18/15 10:28 AM